📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Redirecting anti-Vaccinia virus T cell immunity for cancer treatment by AAV-mediated delivery of the VV B8R gene. (2022)

First Author: Cao D

Attributed to: Pre-clinical development for IND application of a novel systemically deliverable oncolytic Vaccinia virus for treatment of pancreatic cancer funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.omto.2022.04.008

PubMed Identifier: 35615262

Publication URI: http://europepmc.org/abstract/MED/35615262

Type: Journal Article/Review

Volume: 25

Parent Publication: Molecular therapy oncolytics

ISSN: 2372-7705